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A B S T R A C T
Aim. – The oral glucose tolerance test (OGTT), widely used as a gold standard for gestational diabetes
mellitus (GDM) diagnosis, provides a broad view of glucose pathophysiology in response to a glucose
challenge. We conducted the present study to evaluate metabolite changes before and after an oral
glucose challenge in pregnancy; and to examine the extent to which metabolites may serve to predict
GDM diagnosis in pregnant women.
Methods. – Peruvian pregnant women (n = 100) attending prenatal clinics (mean gestation 25 weeks)
participated in the study with 23% of them having GDM diagnosis. Serum samples were collected
immediately prior to and 2-hours after administration of a 75-g OGTT. Targeted metabolic proﬁling was
performed using a LC-MS based metabolomics platform. Changes in metabolite levels were evaluated
using paired Student’s t-tests and the change patterns were examined at the level of pathways.
Multivariate regression procedures were used to examine metabolite pairwise differences associated
with subsequent GDM diagnosis.
Results. – Of the 306 metabolites detected, the relative concentration of 127 metabolites were
statistically signiﬁcantly increased or decreased 2-hours after the oral glucose load (false discovery rate
[FDR] corrected P-value < 0.001). We identiﬁed relative decreases in metabolites in acylcarnitines, fatty
acids, and diacylglycerols while relative increases were noted among bile acids. In addition, we found
that C58:10 triacylglycerol (b = 0.08, SE = 0.04), C58:9 triacylglycerol (b = 0.07, SE = 0.03), adenosine
(b = 0.70, SE = 0.32), methionine sulfoxide (b = 0.36, SE = 0.13) were signiﬁcantly associated with GDM
diagnosis even after adjusting for age and body mass index.
Conclusions. – We identiﬁed alterations in maternal serum metabolites, representing distinct cellular
and metabolic pathways including fatty acid metabolism, in response to an oral glucose challenge. These
ﬁndings offer novel perspectives on the pathophysiological mechanisms underlying GDM.
C 2018 Elsevier Masson SAS. All rights reserved.
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Gestational diabetes mellitus (GDM), or impaired glucose intoler-
ance ﬁrst diagnosed during pregnancy, is one of the most common
medical complications of pregnancy [1]. Annually, it is estimated to* Corresponding author. Department of Epidemiology, Harvard T.H. Chan School
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1262-3636/C 2018 Elsevier Masson SAS. All rights reserved.affect approximately 8% of pregnancies in the US [2] and 5% globally
[3,4]. GDM is associated with increased risk of caesarean and operative
vaginal delivery, macrosomia, intrauterine growth retardation,
shoulder dystocia, neonatal hypoglycaemia, hypocalcaemia, and
hyperbilirubinemia [5–7]. Recently, the International Diabetes
Federation reported that approximately 16% of live births were
complicated by hyperglycaemia during pregnancy and the frequency
of GDM affected pregnancies is most likely to increase concurrently
with the increase in risk factors like obesity and physical inactivity [3].gnatures associated with an oral glucose challenge in pregnant
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shown to progressively become insensitive to insulin and insulin-
mediated whole-body glucose disposal decreases by 50% and
insulin secretion by 200–250%, in order to maintain a euglycaemic
state [8]. In pregnancies complicated by GDM, however, the
increased demand for insulin is not met due to inadequate
pancreatic b-cell function leading to inadequate compensation for
the body’s insulin needs [9]. Of note, a subgroup of women with a
history of GDM is at increased risk of developing type 2 diabetes
mellitus (T2DM) postpartum [10]. However, the underlying
metabolic pathophysiology of GDM is not well understood [11].
Emerging metabolomics technologies that enable systemic
analysis of small molecules in biological specimens have been
successfully used to provide a novel and deeper insight in the
etiopathogenesis of diseases [11]. Metabolomics provides an
integrated proﬁle of biological status by identifying biochemical
changes before the onset of overt clinical disease [12–
16]. Relatively few studies have been conducted to assess the
underlying metabolic pathophysiology of GDM and no adequate
predictive methods are available for GDM thus posing a clear
need to develop non-invasive and objective diagnostic methods
[11,12,17,18].
The oral glucose tolerance test (OGTT) is widely used as a gold
standard for GDM diagnosis and provides a broad view of glucose
pathophysiology in response to a glucose challenge [19]. There-
fore, we designed a study to systematically characterize acute
maternal metabolic changes subsequent to a 75 g oral glucose
challenge in late pregnancy. We reasoned that the application of
metabolomics methods in the context of clinical obstetrics will
yield insights into metabolic alternations underlying GDM
pathogenesis and lead to the discovery of additional diagnostic
or prognostic biomarkers [20].
Methods
Participants and study setting
This analysis used data initially gathered for the Screening,
Treatment and Effective Management of Gestational Diabetes
Mellitus (STEM-GDM) study, a cohort study designed to evaluate
the prevalence of GDM using the new diagnostic criteria proposed
by the International Association of Diabetes and Pregnancy Study
Groups (IADPSG) among Peruvian women attending perinatal care
at Instituto Nacional Materno Perinatal (INMP) in Lima, Peru
[21,22]. The INMP, overseen by the Peruvian Ministry of Health, is
the primary referral hospital for maternal and perinatal care.
Recruitment period was between February 2013 and February
2014. Women who initiated prenatal care before 28 weeks’
gestation were eligible to participate. Women were ineligible if
they were younger than 18 years of age, did not speak and read
Spanish, did not plan to carry the pregnancy to term or deliver at
INMP, and/or were past 28 weeks’ gestation.
Enrolled subjects were asked to participate in a structured
interview that gathered information regarding sociodemographic,
lifestyle, medical, and reproductive characteristics between 24–28
weeks gestation (25 weeks gestation, on average). After an 8-hour,
overnight fast, participants underwent a 75 g, 2-hour OGTT.
Fasting and 2-hour blood samples were collected, processed,
and stored at 80 8C until analyzed. Following the blood sample
collection, a brief physical examination was administered by a
trained research nurse who took anthropometric measures
including standing height and weight. All participants provided
informed consent and the research protocol was approved by the
Institutional Review Boards of the INMP, Lima, Peru and the
Harvard T. H. Chan School of Public Health Ofﬁce of Human
Research Administration, Boston, MA, USA.Please cite this article in press as: Gelaye B, et al. Metabolomics si
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The analytical population was derived from participants who
enrolled in the STEM-GDM Cohort between February 2013 and
February 2014. During this period, a total of 1,032 women
participated in the study. A total of 100 women were randomly
selected for the present metabolomics analysis. The 100 randomly
selected women for this analysis did not differ in regards to
sociodemographic and lifestyle characteristics as compared with
the total cohort.
Metabolic proﬁling
Fasting blood samples were collected at 25 weeks of gestation,
on average, after an overnight fast, both immediately prior to and
2-hours after administration of 75-g OGTT. Samples were
protected from ultraviolet light, kept on wet ice and centrifuged
within 20 minutes of phlebotomy. Serum samples were stored at
80 8C until assayed. Four liquid chromatography-tandem mass
spectrometry (LC-MS) methods were used to proﬁle serum polar
metabolites and lipids. Negative ion mode, targeted MS analyses of
polar metabolites were conducted as described previously
[23]. Brieﬂy, LC-MS samples were prepared from serum (30 mL)
via protein precipitation with the addition of four volumes of 80%
methanol containing inosine-15N4, thymine-d4 and glycocholate-
d4 internal standards (Cambridge Isotope Laboratories; Andover,
MA). The samples were centrifuged (10 min, 9000  g, 4 8C) and the
supernatants were analysed using an ACQUITY UPLC (Waters,
Milford MA) coupled to a 5500 QTRAP triple quadrupole mass
spectrometer (AB SCIEX, Framingham, MA). Extracts (10 mL) were
injected directly onto a 150  2.0 mm Luna NH2 column (Pheno-
menex; Torrance, CA). The column was eluted at a ﬂow rate of
400 mL/min with initial conditions of 10% mobile phase A (20 mM
ammonium acetate and 20 mM ammonium hydroxide in water)
and 90% mobile phase B (10 mM ammonium hydroxide in 75:25 v/
v acetonitrile/methanol) followed by a 10 min linear gradient to
100% mobile phase. MS data were acquired using multiple reaction
monitoring scans tuned for each compound using authentic
reference standards. The ion spray voltage was 4.5 kV and the
source temperature was 500 8C. Raw data were processed using
MultiQuant 2.1 software (SCIEX, Framingham MA). Non-targeted,
positive ion mode analyses of polar metabolites and lipids were
conducted using two separate methods as described previously
[24]. Data for both methods were acquired using a Nexera X2 U-
HPLC system (Shimadzu Scientiﬁc Instruments; Marlborough, MA)
coupled to a Q Exactive Orbitrap mass spectrometer (Thermo
Fisher Scientiﬁc; Waltham, MA). Polar metabolites were extracted
from body ﬂuids and tissue homogenates (10 mL) using addition of
nine volumes of 74.9:24.9:0.2 v/v/v acetonitrile/methanol/formic
acid containing stable isotope-labelled internal standards (valine-
d8, Isotec; and phenylalanine-d8, Cambridge Isotope Laboratories;
Andover, MA). The extracts were centrifuged (10 min, 9000  g,
4 8C), and the supernatants were injected onto a 150  2 mm
Atlantis HILIC column (Waters; Milford, MA). The column was
eluted isocratically at a ﬂow rate of 250 mL/min with 5% mobile
phase A (10 mM ammonium formate and 0.1% formic acid in
water) for 1 minute followed by a linear gradient to 40% mobile
phase B (acetonitrile with 0.1% formic acid) over 10 minutes. Polar
metabolite MS analyses were carried out using electrospray
ionization in the positive ion mode, using full scan analysis over
m/z 70–800 at 70,000 resolution and 3 Hz data acquisition rate.
Additional MS settings were: ion spray voltage, 3.5 kV; capillary
temperature, 350 8C; probe heater temperature, 300 8C; sheath
gas, 40; auxiliary gas, 15; and S-lens RF level 40. Lipids were
extracted from plasma and lung tissue homogenates (10 mL) using
190 mL of isopropanol containing 1-dodecanoyl-2-tridecanoyl-sn-gnatures associated with an oral glucose challenge in pregnant
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Table 1
Characteristics of Study Population (n = 100).
Characteristics n
Gestational age (weeks)a 25.6  1.2
Maternal age (years) 28.7  6.6
18–19
20–29 54
30–34 19
 35 22
Marital status
Married/living with partner 84
Other 16
Employed during pregnancy 28
Smoked before pregnancy 20
Smoked during pregnancy 1
Alcohol consumption before pregnancy 29
Alcohol consumption during pregnancy 4
Nulliparous 34
Body mass index (kg/m2)a 28.2  3.9
Body mass index (kg/m2)
< 18.5 23
18.5–24.9 48
25.0–29.9 23
 30.0 6
Diagnosed gestational diabetesb 23
a Data in mean  SD or number (%).
b Gestational diabetes (GDM) deﬁned according to the International Association
for Diabetes and Pregnancy Study Group with fasting glucose  92 mg/dL [25]. BMI
at the time of testing.
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Lipids; Alabaster, AL). After centrifugation (10 min, 9,000  g,
ambient temperature), supernatants (2 mL) were injected directly
onto a 100  2.1 mm ACQUITY BEH C8 column (1.7 mm; Waters;
Milford, MA). The column was eluted at a ﬂow rate of 450 mL/min
isocratically for 1 minute at 80% mobile phase A (95:5:0.1 vol/vol/
vol 10 mM ammonium acetate/methanol/acetic acid), followed by
a linear gradient to 80% mobile-phase B (99.9:0.1 vol/vol
methanol/acetic acid) over 2 minutes, a linear gradient to 100%
mobile phase B over 7 minutes, and then 3 minutes at 100%
mobile-phase B. MS analyses were carried out using electrospray
ionization in the positive ion mode using full scan analysis over m/
z 200–1100 at 70,000 resolution and 3 Hz data acquisition rate.
Additional MS settings were: ion spray voltage, 3.0 kV; capillary
temperature, 320 8C; probe heater temperature, 300 8C; sheath
gas, 50; auxiliary gas, 15; and S-lens RF level 60.
Laboratory analytical procedures
Fasting blood samples were collected and processed in
accordance with standard international procedures using the
glucose oxidase method. The diagnosis of GDM was determined
using the new IADPSG recommendations [25]. With this deﬁnition,
the diagnosis of GDM was made when any of the following values
from the 75-g OGTT is equaled or exceeded: fasting plasma glucose
5.1 mmol/L, 1-h plasma glucose 10.0 mmol/L, or 2-h plasma
glucose 8.5 mmol/L.
Other covariates
Maternal body mass index (BMI) was calculated as weight in
kilograms divided by height in square meters (kg/m2). Categories
of BMI were characterized as normal weight (< 25 kg/m2),
overweight (25–29.9 kg/m2), and obese ( 30 kg/m2). Maternal
age was categorized as follows: < 19, 20–29, 30–34,  35 years.
Other social and demographic variables were categorized as:
maternal education ( 6, 7–12, and > 12 completed years of
schooling), nulliparous (yes vs. no), marital status (married or
living with partner vs. single or living alone/divorced), difﬁculties
to pay for necessities like food (very hard/hard, somewhat hard,
and not hard), and difﬁculties to access medical care (very hard/
hard, somewhat hard, and not hard).
Statistical analysis
After excluding 19 metabolites with more than 20% missing or
undetectable values, a total of 306 metabolites were analyzed.
Metabolites were transformed on the natural logarithmic scale due
to skewed distribution. Paired Student’s t-tests were performed to
examine the difference in metabolite levels between the two-time
points (fasting and 2-hours post-glucose challenge). To account for
multiple testing, a false discovery rate (FDR) procedure was
applied [26]. For each metabolite, fold change was determined by
taking the mean of the ratios of the log-transformed values
between the two-time points for everyone. Then, we used two
approaches to compute risk scores of metabolites associated with
GDM. In the ﬁrst approach, we used principal component analysis
(PCA) and evaluated the association between the ﬁrst principal
component and GDM status using logistic regression, as the ﬁrst
principal component is the one that explains the maximum
amount of variance possible in the dataset. The risk score was
deﬁned as the product of the estimated regression coefﬁcient and
the value of the ﬁrst principal component. For the second
approach, we used logistic regression models to examine the
relation between each metabolite within pathways and GDM
status. Scores were computed by multiplying the delta value ofPlease cite this article in press as: Gelaye B, et al. Metabolomics si
women. Diabetes Metab (2018), https://doi.org/10.1016/j.diabet.201each metabolite with its corresponding effect size then summing
these products across all metabolites. A leave-one-out cross-
validation procedure was implemented to protect against model
over-ﬁtting. Thus, successively one observation was left out from
the sample (n), the remaining observations (n-1) constituted the
training set and the left-out one the validation set. Each time, and
for both approaches, regression coefﬁcients were estimated on the
training set. This process was repeated n times until all
observations were validated. Scores were calculated for the
validation set using estimated regression coefﬁcients from the
training set. Once all scores were computed a logistic regression
model was ﬁt to examine the association of the scores with GDM
status. All statistical analyses were conducted using R [27].
Results
The socio-demographic characteristics of the participants are
presented in Table 1. A total of 100 pregnant women between the
ages of 18 and 45 years (mean age = 28.6 years, standard
deviation = 6.6 years) with mean gestational age of 25.6 weeks
(SD = 1.2 weeks) participated in the study. Most participants were
married or living with their partner (84.0%) while 28.5% were
employed during pregnancy. Approximately 20% of participants
reported smoking before pregnancy while 29% reported alcohol
consumption before index pregnancy. Only 1% reported smoking
during index pregnancy while 4% reported alcohol consumption
during pregnancy. Gestational diabetes (deﬁned according to the
international association for diabetes and pregnancy study group
with fasting glucose  92 mg/dL) was present in 23% of study
participants.
Out of the 306 metabolites that were detected, the relative
abundance of 127 metabolites had a statistically signiﬁcantly
increase or decrease after OGTT (FDR-corrected P-value < 0.001).
Most metabolites decreased in response to OGTT (Table 2a and
Supplemental Figure 1a; see supplementary materials associated
with this article online) while a few increased in response to OGTT
(Table 2b and Supplemental Figure 1b; see supplementary
materials associated with this article online). The largest relativegnatures associated with an oral glucose challenge in pregnant
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Table 2a
Metabolites that decreased after glucose challenge (FDR adjusted paired t-test P-value < 0.001).
Metabolite Pathway group Mean change SD Fold changea
C8 carnitine Acylcarnitines 1.45 0.95 1.20
C14:2 carnitine Acylcarnitines 1.15 0.53 1.13
C12 carnitine Acylcarnitines 1.07 0.56 1.13
C4-OH carnitine Acylcarnitines 0.95 0.64 1.13
C14:1 carnitine Acylcarnitines 1.09 0.53 1.13
C10 carnitine Acylcarnitines 1.04 0.57 1.11
5-HETE Fatty acid 1.00 0.96 1.10
C6 carnitine Acylcarnitines 0.76 0.40 1.09
C12:1 carnitine Acylcarnitines 1.07 0.55 1.08
C10:2 carnitine Acylcarnitines 0.60 0.38 1.08
C14 carnitine Acylcarnitines 0.57 0.47 1.07
C30:0 DAG Diacylglycerols 0.61 0.59 1.07
Palmitoleic acid Fatty acid 1.26 0.43 1.07
Gamma-Linolenic acid Fatty acid 1.18 0.47 1.06
C32:2 DAG Diacylglycerols 0.56 0.69 1.06
Aspartate Amino acid 0.54 0.40 1.06
Methionine sulfoxide Amino acid 0.44 0.56 1.06
Glycine Amino acid 0.34 0.34 1.06
Alpha-glycerophosphocholine Glycerophospholipids 0.70 0.35 1.06
Allantoin Purine 0.43 0.61 1.05
Docosapentaenoic acid Fatty acid 0.84 0.38 1.05
C18:2 carnitine Acylcarnitines 0.46 0.38 1.05
Adrenic acid Fatty acid 0.79 0.34 1.05
C9 carnitine Acylcarnitines 0.60 0.54 1.05
Eicosapentaenoic acid Fatty acid 0.77 0.36 1.05
C18:1 carnitine Acylcarnitines 0.47 0.34 1.05
Glutamate Amino acid 0.48 0.32 1.05
Leucine Amino acid 0.56 0.26 1.04
Isoleucine Amino acid 0.52 0.22 1.04
8.11.14-Eicosatrienoic acid Fatty acid 0.67 0.30 1.04
Methionine Amino acids 0.42 0.23 1.04
Citrulline Amino acid 0.38 0.20 1.04
Serine Amino acid 0.37 0.22 1.04
Linoleic acid Amino acid 0.70 0.28 1.04
Phenylalanine Amino acid 0.47 0.27 1.04
Oleic acid Fatty acid 0.67 0.26 1.03
Thiamine Amino acids 0.46 0.37 1.03
C18:0 LPE Lysophosphatidylethanolamines 0.33 0.33 1.03
Tyrosine Amino acid 0.39 0.23 1.03
Docosahexaenoic acid Fatty acid 0.58 0.30 1.03
C2 carnitine Acylcarnitines 0.43 0.30 1.03
Asparagine Amino acid 0.29 0.19 1.03
Niacinamide Amino acid 0.28 0.42 1.03
Homocysteine Amino acid 0.29 0.64 1.03
C16 carnitine Acylcarnitines 0.26 0.21 1.03
Palmitic acid Fatty acid 0.51 0.18 1.03
Taurine Biogenic amines 0.33 0.43 1.03
Valine Amino acids 0.30 0.17 1.03
Arachidonic acid Fatty acid 0.45 0.36 1.02
C32:1 DAG Diacylglycerols 0.29 0.21 1.02
Hydroxyproline Amino Acid 0.25 0.18 1.02
C16:0 LPE Lysophosphatidylethanolamines 0.24 0.33 1.02
C42:0 TAG Triacylglycerol 0.25 0.36 1.02
Ornithine Biogenic amines 0.23 0.25 1.02
C18:1 LPE Lysophosphatidylethanolamines 0.20 0.41 1.02
Kynurenic acid Amino Acid 0.19 0.35 1.02
Arginine Amino acid 0.31 0.20 1.02
C32:0 DAG Diacylglycerols 0.25 0.19 1.02
C34:0 DAG Diacylglycerols 0.23 0.17 1.02
Myristic acid Fatty acid 0.38 0.16 1.02
Stearic acid Fatty acid 0.37 0.18 1.02
C18:0 LPC Lysophosphatidylcholines 0.28 0.24 1.02
Threonine Amino acids 0.19 0.15 1.02
C34:3 DAG Diacylglycerols 0.18 0.20 1.02
Choline Amino Acid 0.22 0.24 1.02
a Fold change represents mean of log-pre-OGTT/log-post-OGTT value.
B. Gelaye et al. / Diabetes & Metabolism xxx (2018) xxx–xxx4
G Model
DIABET-970; No. of Pages 8decrease after OGTT was seen in C8 carnitine which decreased by
20%, followed by C14:2 carnitine, C14:1 carnitine, C12 carnitine,
and C4-OH carnitine which decreased by 13% each. The largest
relative increases after OGTT were seen in adenosine and
taurolithocholic acid, which increased by 25% and 12% respective-
ly. Fig. 1 shows a heat map of partial Pearson correlationPlease cite this article in press as: Gelaye B, et al. Metabolomics si
women. Diabetes Metab (2018), https://doi.org/10.1016/j.diabet.201coefﬁcients of metabolite concentrations between before and
after responses to OGTT, adjusted for gestational age and grouped
by pathways. We found that baseline concentrations of metabo-
lites in common biological pathways were correlated after OGTT.
Higher positive correlations were noted for carnitines while higher
negative correlations were noted for triacylglycerols.gnatures associated with an oral glucose challenge in pregnant
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Table 2b
Metabolites that increased after glucose challenge (FDR adjusted paired t-test P-
value < 0.001).
Metabolite Pathway group Mean change SD Fold changea
Adenosine Purine 1.64 1.32 1.25
Taurolithocholic acid Bile acid 1.28 1.14 1.12
Glycolithocholic acid Bile acid 0.69 0.88 1.06
Glycochenodeoxycholic acid Bile acid 0.87 0.85 1.06
Taurochenodeoxycholic acid Bile acid 0.73 0.93 1.05
Taurodeoxycholic acid Bile acid 0.68 0.89 1.05
Glycoursodeoxycholic acid Bile Acid 0.56 0.96 1.05
Glycodeoxycholic acid Bile acid 0.69 0.75 1.05
Taurocholic acid Bile acid 0.53 0.95 1.04
Glycocholic acid Bile Acid 0.50 0.97 1.04
Phosphocholine Organonitrogen 0.42 0.70 1.03
a Fold change represents mean of log-post-OGTT/log- pre-OGTT value.
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groups of metabolic pathways. For example, major decreases in
metabolite levels were noted in acylcarnitine, fatty acid and
diacylglycerol pathways where more than a 10% decrease in
relative concentration was noted in the following metabolites:
carnitines C12:2, C14:1, C12, C10:2 and C8. A major increase in
concentration was noted in metabolites of bile acid pathway whereFig. 1. Heat-map of partial Pearson correlation coefﬁcients adjusted for gestational 
Please cite this article in press as: Gelaye B, et al. Metabolomics si
women. Diabetes Metab (2018), https://doi.org/10.1016/j.diabet.201adenosines increased by more than 20% and taurolithocholic acid
increased by more than 10%.
In analyses using linear regression procedures on each
metabolite versus GDM status, we found that C58:10 triacyl-
glycerol, C58:9 triacylglycerol, adenosine, and methionine sulfox-
ide were signiﬁcantly associated with GDM status even after
adjusting for age and BMI (Table 3a).
Next, to identify a linear combination of metabolites that might
be associated with of GDM, we calculated risk scores using two
approaches. In the ﬁrst approach, we performed a PCA on
normalized data (Table 3b). The association between the ﬁrst
principal component (representing 88% of variability) and GDM
status was examined using a logistic regression model. The
corresponding risk score computed by multiplying the ﬁrst
principal component by its effect size was found to be signiﬁcantly
associated with GDM risk (coefﬁcient = 29.37, SE = 8.6,
P < 0.001). The distribution of the scores by GDM status are
shown in Supplemental Figures 2a and b (see supplementary
materials associated with this article online). Overall, the median
scores for GDM women were lower in amino acids and
glycerophospholipids while they are relatively higher for lyso-
phosphatidylcholines, as compared with non-GDM women. In the
second approach, each metabolite’s relation with GDM status was
analyzed using univariate logistic regression models and scoresage for the 127 signiﬁcantly changed metabolites ordered by pathway groups.
gnatures associated with an oral glucose challenge in pregnant
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Fig. 2. Changes in metabolite levels in response to two-hour post challenge are shown. Metabolites were ordered by pathway groups.
Table 3a
Differences in metabolite levels in response to OGTT between GDM and non GDM
cases.
Metabolite Adjusted for age Adjusted for age and BMI
Estimate SE P-value Estimate SE P-value
C58:10 TAG 0.085 0.037 0.030 0.082 0.037 0.031
C58:9 TAG 0.069 0.033 0.041 0.069 0.033 0.042
Adenosine 0.705 0.321 0.031 0.705 0.322 0.031
Methionine sulfoxide 0.356 0.131 0.008 0.357 0.131 0.008
Table 3b
Effect of scores on GDM status evaluated by logistic regression.
Estimate SE P-value
Score based on pca 29.3788 8.6236 < 0.001
Score based on univariate analysis
Normalized 0.1714 0.05857 0.003
B. Gelaye et al. / Diabetes & Metabolism xxx (2018) xxx–xxx6
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concentrations at baseline and post-OGTT with its corresponding
regression coefﬁcient and taking the sum over all metabolites. This
score is also found to be associated with GDM status (b
coefﬁcient = 0.113, SE = 0.046, P = 0.0143).Please cite this article in press as: Gelaye B, et al. Metabolomics si
women. Diabetes Metab (2018), https://doi.org/10.1016/j.diabet.201Discussion
Using a targeted metabolomics approach, we found signiﬁcant
metabolic differences in various biological pathways in response to
a glucose challenge during pregnancy. Speciﬁcally, we identiﬁed
relative decreases in acylcarnitine, fatty acid, and diacylglycerol
pathways while relative increases were noted in bile acid
pathways. In addition, we found that C58:10 triacylglycerol,
C58:9 triacylglycerol, adenosine, and methionine sulfoxide were
signiﬁcantly associated with GDM status even after adjusting for
age and BMI.
Our ﬁndings showing decreases in acylcarnitines and diacyl-
glycerols following glucose ingestion are not surprising [12]. Acyl-
carnitines, involved in b-oxidation of fatty acid or amino acid
metabolism, are markers of mitochondrial dysfunction [28] and
have been implicated in insulin resistance and energy homeostasis
[29]. Moreover, acylcarnitines are synthesized by the enzyme
carnitine palmitoyltransferase 1 (CPT 1) that is known to be
responsible for the transport of long-chain fatty acids into the
mitochondrial matrix [30]. Fatty acids can be metabolized via a
mitochondrial FA oxidation (FAO) pathway which yields energy.
The FAO competes with glucose oxidation in a process known as
glucose-FA or Randle cycle [29]. Available evidence suggests that
acylcarnitines play a signiﬁcant role in energy metabolism and
GDM pathogenesis [31]. Investigators have also postulated an
alternative mechanism in which FAO rate outpaces the tricarbox-
ylic acid cycle (TCA) thereby leading to the accumulation ofgnatures associated with an oral glucose challenge in pregnant
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with insulin sensitivity [29].
Lipotoxicity, excess lipid supply and accumulation, has been
one of the theories proposed for the induction of insulin resistance
in glucose and lipid metabolism [29,32]. Diacylglycerols (DAG) are
lipid intermediates that have been implicated in insulin resistance
and are signalling molecules and building blocks of cellular
membranes, which harbour the insulin receptor. Animal studies
have demonstrated that long-term ingestion of DAG prevents high
fat-induced body weight gain and fat accumulation [33,34]. Our
study results showing decreases in DAG following glucose
ingestion conﬁrm prior observation in animal [35] and human
studies [36] suggesting a key role for lipid intermediates such as
DAG in the development of metabolic disorders such as GDM.
Our ﬁndings showing post-glucose increases in conjugated bile
acid pathways are consistent with prior studies [12]. It has long
been known that bile acids are amphipathic molecules that
function as powerful detergents to facilitate absorption of lipids
and nutrients and excretion of cholesterol and toxic metabolites
[37]. In response to glucose ingestion, cholecystokinin stimulates
the gallbladder to contract and release bile into the enterohepatic
circulation [38]. Several lines of evidence have demonstrated that
bile acids play important roles in glucose regulation and energy
homeostasis [39,40]. For example, studies from animal models
have shown that the primary bile acids such as cholic acid
synthesized from hepatic cholesterol increases energy expenditure
and prevents the development of high-fat-induced obesity and
insulin resistance [41]. These metabolic effects of bile acid are
mediated by the G-protein-coupled receptor TGR5, leading to the
induction of type-2 iodothyronine deiodinase. Recently, Vincent
et al. have found that the postprandial bile acid response in obese
patients with type-2 diabetes mellitus is greater than that in
normoglycaemic individuals [42]. In the past decade, there has
been an increased recognition that bile acids are natural ligands for
the farnesoid X receptor (FXR-a) and were found to activate
speciﬁc nuclear receptors such as pregnane X receptor, vitamin D
receptor, G protein-coupled receptors and cell signalling pathways
[43]. A recent study by Fall et al. found that increased concen-
trations of three 12a-hydroxylated bile acids (deoxycholic acid,
glycocholic acid, and glycodeoxycholic acid) were associated with
incident diabetes [44]. In addition, a genetic variant within the
CYP7A1 locus, encoding the rate-limiting enzyme in bile acid
synthesis, was found to be associated with lower type-2 diabetes
risk [44]. Collectively these observations, coupled with our
ﬁndings, provide additional insights into the key role bile acid
pathways play in the pathogenesis of GDM and other metabolic
disorders.
We found a sub-group of maternal metabolites (i.e., C58:10
triacylglycerol, C58:9 triacylglycerol, adenosine, and methionine
sulfoxide) to be statistically signiﬁcantly associated with GDM.
These ﬁndings indicate the roles endothelial dysfunction and
oxidative stress pathways play in the pathophysiology of GDM
[45]. For instance, adenosine acts as a vasodilator in several
vascular beds and acts as a stimulator of endothelial cell
proliferation [46]. Adenosine has been implicated in physiological
responses of different tissues [47,48]. It contributes to endothelial
dysfunction in endothelial cells from the umbilical veins of
patients with GDM [49]. Of note, the transport and metabolism
of adenosine is markedly impaired in foetal endothelial cells
isolated from pregnancies complicated by GDM [47,48]. In
addition, increased concentration of adenosine upregulate expres-
sion of endothelial nitric oxide synthase via A2A adenosine
receptors, which leads to increased nitric oxide synthesis, a
potential cause of vascular dysfunction in GDM [50].
Investigators have reported that methionine sulfoxide can be
considered a marker of oxidative stress and is associated withPlease cite this article in press as: Gelaye B, et al. Metabolomics si
women. Diabetes Metab (2018), https://doi.org/10.1016/j.diabet.201increased high sensitivity c-reactive protein [51,52]. These ﬁn-
dings, if replicated, should facilitate the identiﬁcation of additional
circulating biomarkers suitable for predicting the development or
progression of GDM.
Some strengths and limitations should be considered in
interpreting our study ﬁndings. Using samples before and after
glucose ingestion allowed subjects to serve as their own biological
controls. This eliminated confounding by subject characteristics.
However, there are several caveats that merit consideration. First,
the cross-sectional design of our study does not allow for
determination of the temporal relationship between perturbations
of metabolites and GDM risk although the changes in metabolites
were in agreement with known physiological actions of glucose.
Longitudinal studies are needed following women earlier in their
pregnancies. Second, the changes observed in metabolites were in
relative concentrations. We were not able to provide absolute
concentrations of metabolites. Absolute quantiﬁcation of metab-
olites is a future area of investigation. Lastly, our study had a
limited sample size and was conducted in women attending
prenatal clinics in Peru and hence may not be generalizable to
other populations.
In summary, we identiﬁed changes in several metabolites
representing distinct biological pathways during an OGTT offering
novel perspectives on the GDM pathogenesis. We found relative
decreases in acylcarnitine, fatty acid, and diacylglycerol pathways
while relative increases were noted in bile acid pathways. In
addition, we found that C58:10 triacylglycerol, C58:9 triacyl-
glycerol, adenosine, and methionine sulfoxide were signiﬁcantly
associated with GDM status even after adjusting for age and BMI.
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